
A new device developed by University of Cincinnati researchers could appear as a blessing for women who experience severe menstrual pain.
Fed up of the chronic pain, women often end up having medications that can cause gastrointestinal side effects.
Advertisement
Clinical trials have shown that the new vaginal device safely delivers at least 10-times more drug to the uterus as a tablet of equivalent dose.
During the study, the researchers recruited 18 participants, aged 18-45 years with menstrual cycles between 25-30 days.
In the mid-follicular phase of the first menstrual cycle (days 7-11), nine study participants received an oral dose of 10 mg of ketorolac (Toradol), a non-steroidal anti-inflammatory medication; while nine women received a tampon coated with 10 mg of ketorolac.
During the second menstrual cycle, each subject received the opposite treatment.
The results revealed that the medication administered vaginally does not cause significant side effects but accumulates more efficiently in the desired uterine tissue than using the oral medication.
"While still early in our research, this study shows promising results which may help pave the way for new treatment options for women," said Dr Giovanni M. Pauletti, associate professor at the University of Cincinnati.
"Phase II clinical trials will study efficacy of the treatment to assess whether the drug concentration is effective in reducing pain," Pauletti added.
The study was presented at American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition.
Source: ANI
ARU
In the mid-follicular phase of the first menstrual cycle (days 7-11), nine study participants received an oral dose of 10 mg of ketorolac (Toradol), a non-steroidal anti-inflammatory medication; while nine women received a tampon coated with 10 mg of ketorolac.
Advertisement
During the second menstrual cycle, each subject received the opposite treatment.
The results revealed that the medication administered vaginally does not cause significant side effects but accumulates more efficiently in the desired uterine tissue than using the oral medication.
"While still early in our research, this study shows promising results which may help pave the way for new treatment options for women," said Dr Giovanni M. Pauletti, associate professor at the University of Cincinnati.
"Phase II clinical trials will study efficacy of the treatment to assess whether the drug concentration is effective in reducing pain," Pauletti added.
The study was presented at American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition.
Source: ANI
ARU
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Women Health News

An AI tool called Flan-T5 identified postpartum hemorrhage with 95% precision and detected 47% patients with the condition.

Active surveillance of cervical lesions was associated with higher cervical cancer risk in the long term compared to its removal.

Japan initiated the trial of selling morning-after contraceptive tablets over-the-counter in an effort to lower abortion rates and solace for rape victims.

The rising number of urinary tract infections (UTIs) among Indian women can be attributed primarily to social stigma and a lack of awareness.

Pregnant women with Sjogren's or lupus syndrome have elevated anti-Ro/SSA antibodies which are linked to fetal atrioventricular block in the heart.